RSS Feed

News


Australia based Cellmid has recently announced that its wholly owned subsidiary Advangen Limited (“Advangen”) has entered into an exclusive agreement with Beijing Fukangren Bio-pharm Techto distribute its évolis anti-aging hair care products in the Peoples Republic of China.
The Weekend Australian Interviews Cellmid Director Dennis Eck
Proven strategies across the marketing spectrum for businesses big and small, delivered by Peter Applebaum and a team of experts. Featuring Maria Halasz.
Cellmid Limited (ASX:CDY) will be convening the 5th Midkine Symposium in Munich, Germany between 3rd and 5th May 2018.
Cellmid Limited (ASX:CDY) (the Company) advises that it has entered into an agreement with Labo International S.r.l to undertake the exclusive distribution of Fillerina®, a market leading Swiss anti-aging skincare brand, in Australia and New Zealand for up to an initial five years.
Cellmid Limited (ASX: CDY) is pleased to advise that a manuscript describing the screening approach and clinical study carried out by Cellmid’s wholly owned subsidiary, Advangen Limited, has been published in the journal Clinical, Cosmetic, and Investigational Dermatology 10: 71-85. 27 Feb 2017.
Cellmid Limited (ASX: CDY) is pleased to advise that the European Patent Office has issued Notice of Allowance for the patent application number 11746751.4 entitled “Method of Treatment or Prevention of Hair Loss or for Enhancement of Hair Growth” (midkine or MK alopecia patent).
Cellmid Limited (ASX: CDY) is pleased to advise that the US Patent and Trademark Office has issued Notice of Allowance for the patent application number 14/464,358 entitled “Method of Treatment or Prevention of Hair Loss or for Enhancement of Hair Growth” (midkine or MK alopecia patent).
Cellmid Limited (ASX: CDY) provides this update to shareholders on recent developments regarding its midkine diagnostic license to Pacific Edge Biotechnology Limited (Pacific Edge).
"Hair growth equals Sales Growth equals Share Price Growth" Lodge Partners Analyst Marc Sinatra reports on Cellmid Limited